Zacks Research Has Pessimistic View of Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Investment analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Surmodics in a research note issued on Tuesday, April 29th. Zacks Research analyst D. Dey now expects that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.02. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at $0.08 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.04 EPS, Q1 2027 earnings at $0.10 EPS, Q2 2027 earnings at $0.11 EPS and FY2027 earnings at $0.38 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The firm had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

A number of other equities research analysts have also issued reports on SRDX. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a research note on Friday, March 7th. Finally, StockNews.com initiated coverage on Surmodics in a report on Monday, February 3rd. They set a "hold" rating on the stock. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Surmodics currently has an average rating of "Hold" and a consensus price target of $43.00.

Surmodics Trading Down 1.0 %

NASDAQ SRDX traded down $0.28 during mid-day trading on Thursday, hitting $26.69. The company's stock had a trading volume of 12,452 shares, compared to its average volume of 276,382. The stock's fifty day simple moving average is $29.25 and its two-hundred day simple moving average is $34.78. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44. The firm has a market capitalization of $381.64 million, a P/E ratio of -26.61 and a beta of 1.32.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oddo BHF Asset Management Sas acquired a new position in Surmodics during the third quarter valued at approximately $6,593,000. Principal Financial Group Inc. acquired a new stake in Surmodics in the 3rd quarter worth about $1,190,000. JPMorgan Chase & Co. grew its position in Surmodics by 192.7% during the third quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company's stock worth $1,647,000 after buying an additional 27,960 shares in the last quarter. Barclays PLC grew its stake in Surmodics by 16.0% during the third quarter. Barclays PLC now owns 88,750 shares of the company's stock worth $3,443,000 after buying an additional 12,271 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Surmodics by 22.1% in the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock valued at $275,000 after acquiring an additional 1,255 shares during the last quarter. 96.63% of the stock is currently owned by institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).